Skip to main
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 42%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

Icon is a well-established global company with a strong financial outlook and a focus on social responsibility. Despite a decline in direct-fee book-to-bill, management remains optimistic about future growth and has adjusted their outlook to include revenue growth and improved margins. The company is expected to see significant acceleration in growth in 2027, but potential risks such as government regulations and changes in the biopharma industry should be monitored.

Bears say

Icon is facing several challenges in their business, including potential lower margin rates leading to a decline in EBITDA dollar growth. Additionally, their visibility into passthrough revenues is limited, making it difficult to predict future performance. There are also risks related to further accounting reviews or restatements, failure to deliver trials on time, and securing sensitive clinical trial data. Despite being one of the largest CROs with strong relationships with top pharmaceutical companies, Icon's future financial performance is uncertain, leading to a negative outlook on their stock.

ICON (ICLR) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 42% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 12 analysts, ICON (ICLR) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.